Drug intelligence / Profile preview

Qiwei Fanghua

Development stage: Unknown
Lead developer: Guangdong Yikang Pharmaceutical
Modality: Small Molecules
Administration: Oral

Overview

Qiwei Fanghua is a Traditional Chinese Medicine (TCM) formulation, specifically an oral liquid, developed and manufactured by Guangdong Yikang Pharmaceutical. It is primarily utilized in the clinical management of nasopharyngeal carcinoma (NPC), particularly as an adjuvant therapy to radiotherapy. The formulation is designed to clear heat and detoxify (Qing Re Jie Du) and nourish yin and generate fluids (Yang Yin Sheng Jin), which helps in reducing the toxic side effects of radiation, such as oral mucositis and xerostomia. Clinical studies suggest it may enhance the efficacy of radiotherapy while improving the patient's immune status and overall quality of life.

Brand names: Qiwei Fanghua
Other names: Qiwei Fanghua Oral LiquidQiwei Fanghua Koufuye

Beyond the preview

Go deeper on Qiwei Fanghua.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Qiwei Fanghua.

Explore the full profile